Camilla Fuchs Andersen, ESC 2022: Empagliflozin for HFrEF, the Empire HF trial
The Empire-HF study aimed to investigate the effect of the empagliflozin on erythropoiesis in patients with heart failure with reduced ejection fraction (HFrEF). In this touchCARDIO interview, we speak with Dr Camilla Fuchs Andersen (Herlev Hospital, Herlev, Denmark) to discuss the Empire HF trial and provide an insight into potential mechanisms of empagliflozin on erythropoiesis and iron metabolism. Â
The abstract entitled ‘Direct effects of empagliflozin on erythropoiesis in heart failure: data from the Empire HF trial’ was presented at the European Society of Cardiology (ESC) Congress 2022, 26 – 29 August 2022.
Questions:
- What has been the impact of sodium-glucose co-transporter-2 (SGLT2) inhibitors on patients with heart failure? (0:15)
- What is known about the effect of SGLT2 inhibitors on haematocrit? (0:59)
- What were the aims, design and eligibility criteria of the Empire HF study? (1:43)
- What were the findings of the study? (2:36)
- What mechanisms can explain the observed increased erythropoiesis and changes in iron metabolism with empagliflozin? (3:37)
- What are the clinical implications of these findings? (5:14)
Disclosures: Camilla Fuchs Andersen has nothing to disclose in relation to this video interview.
Support: Interview and filming supported by Touch Medical Media. Interview conducted by Danielle Crosby.
Filmed as a highlight of ESC 2022
Access more content on Heart Failure here
